Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer

The goal of this Phase 3 clinical trial is to evaluate whether continuing cetuximab treatment beyond first-line progression can improve outcomes in patients with metastatic colorectal cancer whose tumors are RAS and BRAF wild-type. The study will compare the effectiveness of chemotherapy given together with cetuximab versus chemotherapy given together with bevacizumab. Researchers aim to determine whether cetuximab continuation improves tumor response, progression-free survival, overall survival, and safety in this patient population. Eligible participants are adults with metastatic colorecta

Trial Details

NCT ID
NCT07389265
Phase
PHASE3
Sponsor
University of Campania Luigi Vanvitelli
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Erbitux (Cetuximab)
  • Bevacizumab
  • FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)
  • FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)
Locations (sample)
  • Ancona, Italy|43.60717,13.5103
  • Avellino, Italy|40.91494,14.79103
  • Aviano, Italy|46.07056,12.59472
  • Bari, Italy|41.12066,16.86982
  • Brescia, Italy|45.53558,10.21472

Key Eligibility Criteria

  • Histologically proven diagnosis of colorectal adenocarcinoma.
  • Diagnosis of metastatic disease.
  • Efficacy of a first line therapy containing anti-EGFR drug with a major response achieved (i.e. complete or partial response according to RECIST cr…
  • Progression to first line therapy.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →